Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 12/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033990 | 0.95 | GRM5 (0.47) | GRM5CCKARMAPTLMNASCN9A | |
| SCHEMBL15033940 | 0.88 | GRM5 (0.62) | GRM5CCKARMAPTSCN9A | |
| SCHEMBL15034002 | 0.87 | GRM5 (0.58) | GRM5MAPTLMNASCN9APOLB | |
| SCHEMBL15033973 | 0.87 | GRM5 (0.54) | GRM5CCKARMAPTSCN9ASMN1; SMN2 | |
| SCHEMBL15034518 | 0.80 | GRM5 (0.53) | GRM5CCKARMAPTPOLBKMT2A | |
| SCHEMBL15034522 | 0.78 | GRM5 (0.50) | GRM5CCKARMAPTLMNAKMT2A | |
| SCHEMBL15023697 | 0.77 | GRM5 (0.53) | GRM5MAPTLMNAPOLBKMT2A | |
| SCHEMBL15034555 | 0.76 | GRM5 (0.54) | GRM5MAPTLMNAPOLBKMT2A | |
| SCHEMBL15025586 | 0.76 | GRM5 (0.78) | GRM5MAPT | |
| SCHEMBL15034554 | 0.76 | POLB (0.44) | GRM5CCKARMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791117-B1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| WO-2013087807-A1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODIULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158011-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | GRM5 1/4885CCKAR 306/4885MAPT 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.